Last reviewed · How we verify
Intravenous Gemini
At a glance
| Generic name | Intravenous Gemini |
|---|---|
| Also known as | Phosphorylated hexaacylated disaccharide, PHAD |
| Sponsor | Revelation Biosciences, Inc |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Evaluation of the Safety and Tolerability of Gemini in Subjects With Stage 3-4 Chronic Kidney Disease. (PHASE1, PHASE2)
- Added Value of 18 FDG Pet-scanner in Diagnosis and Management of Subclinical Rejection in Kidney Transplant Patients (NA)
- Observation Study for Prediction of Allograft Survival and Impact of Imaging in Kidney Transplant Recipients.
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |